GlassScriptPhysician profile
Sarah Keene
NPI 1336697796
$17,223.65
in general payments reported to CMS, 2019-2025
20 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $108 · 2022: $189 · 2023: $178 · 2024: $1,713 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,613 · Consulting Fee: $3,800 · Travel and Lodging: $2,693 · Food and Beverage: $2,471 · Education: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,612.50 |
| Consulting Fee | $3,800.00 |
| Travel and Lodging | $2,693.16 |
| Food and Beverage | $2,470.85 |
| Education | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $10,918.72 | 2023-2025 | |
| Genentech USA, INC. | $4,411.09 | 2024-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Alexion Pharmaceuticals, INC. | $417.52 | 2024 | Ultomiris, Strensiq |
| Genentech, INC. | $354.76 | 2024-2025 | Ocrevus |
| E.R. Squibb & Sons, L.L.C. | $283.46 | 2021-2022 | |
| Abbvie INC. | $268.45 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $112.42 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $109.20 | 2025 | Nuplazid |
| Janssen Biotech, INC. | $70.17 | 2024-2025 | Tremfya, Stelara |
| Celgene Corporation | $50.86 | 2023-2025 | Zeposia |
| Amgen INC. | $44.54 | 2024-2025 | Uplizna, Tavneos |
| Takeda Pharmaceuticals U.S.A., INC. | $36.78 | 2024 | Entyvio |
| Sobi, INC | $22.03 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $21.37 | 2024 | Saphnelo |
| Emd Serono, INC. | $20.46 | 2023 | Mavenclad |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $20.02 | 2024 | Voquezna |
| Sandoz INC. | $17.95 | 2024 | Hyrimoz |
| Vanda Pharmaceuticals INC. | $15.78 | 2025 | Ponvory |
| Smith+Nephew, INC. | $14.39 | 2024 | Collagenase Santyl |
| Collegium Pharmaceutical, INC. | $13.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Keene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.